New market research report on Australia's pharmaceuticals and healthcare industry

20. November 2009 00:20

Research and Markets (http://www.researchandmarkets.com/research/27e3e3/australia_pharmace) has announced the addition of the "Australia Pharmaceuticals and Healthcare Report Q1 2010" report to their offering. [More]

da4e7d85-8c48-4669-83a2-bc1174cf206b|0|.0

Posted in: Healthcare News | Pharmaceutical News

Tags: Diabetes, Metformin, Pfizer, Type 2 Diabetes

Erbitux recognized as one of the major clinical cancer advances of 2009

16. November 2009 09:21

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]

f2838858-9c45-4eb8-a649-a6b5654e9bab|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Acne, Antibody, Cancer, Cell, Cetuximab, Chemotherapy, Colorectal Cancer, Endocrinology, Fertility, Glioblastoma, Head and Neck Cancer, Hypersensitivity, Infertility, Irinotecan, Liposome, Lung Cancer, Metformin, Monoclonal Antibody, Multiple Sclerosis, Non-Small Cell Lung Cancer, Oncology, Oxaliplatin, Radiotherapy, Small Cell Lung Cancer, Smoking, Squamous Cell Carcinoma, Vaccine

Health Canada approves ONGLYZA for the treatment of type 2 diabetes

13. November 2009 04:03

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea). [More]

004f956f-44d8-44ae-ab9a-4d620abba267|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Cardiovascular Disease, Dentistry, Depression, Diabetes, Diet, Exercise, Insulin, Metformin, Neuroscience, Oncology, Onglyza, Saxagliptin, Sulfonylurea, Type 2 Diabetes

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

3. November 2009 03:27

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study. [More]

8a05dac4-7c96-4720-9755-b6fefcd65a75|0|.0

Posted in: Medical Condition News

Tags: Blindness, Blood Pressure, Brain, Cancer, Diabetes, Education, Health Disparities, Hospital, Metformin, Neuroscience, Stroke, Triglyceride, Type 2 Diabetes, Weight Loss

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

3. November 2009 03:07

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection. [More]

35dc2772-9037-45ed-9229-bb4fde20034b|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Brain, Diabetes, Diabetes Mellitus, Diabetic Ketoacidosis, Diarrhea, Diet, Exenatide, Exercise, Gastroparesis, Headache, Hypoglycemia, Insulin, Metabolism, Metformin, Nausea, Nutrition, Obesity, Pancreatitis, Sulfonylurea, Transplant, Type 1 Diabetes, Type 2 Diabetes, Vomiting, Weight Loss

FDA approves an expanded indication for BYETTA injection

31. October 2009 00:31

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. [More]

a2b01897-b631-43e9-80c1-abad4cf86119|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Brain, Diabetes, Diabetes Mellitus, Diabetic Ketoacidosis, Diarrhea, Diet, Exenatide, Exercise, Gastroparesis, Headache, Hypoglycemia, Insulin, Metabolism, Metformin, Nausea, Nutrition, Obesity, Pancreatitis, Sulfonylurea, Transplant, Type 1 Diabetes, Type 2 Diabetes, Vomiting, Weight Loss

Roche discloses the results of first Phase III clinical study using Taspoglutide

29. October 2009 02:45

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research. [More]

a0947d5c-fae4-42d5-9a19-50c5d002c2d6|0|.0

Posted in: Drug Trial News

Tags: Blindness, Diabetes, Diabetes Mellitus, Endocrinology, Exenatide, Insulin, Insulin Glargine, Life Expectancy, Metformin, Nausea, Neurology, Neuropathy, Oncology, Pioglitazone, Renal Failure, Stroke, Vomiting

Proper diet and exercise reduce risk of type 2 diabetes

29. October 2009 01:39

Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent over 10 years in people at high risk for the disease. [More]

7c405e65-b4a9-4781-bd50-8e120c5f3865|0|.0

Posted in: Medical Condition News

Tags: Blood Pressure, Diabetes, Diet, Exercise, Gestational Diabetes, Glucose Metabolism, Hospital, Metabolism, Metformin, Obesity, Stroke, Triglyceride, Type 2 Diabetes, Weight Loss

Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting

26. October 2009 04:37

Santarus, Inc., a specialty biopharmaceutical company, today announced that positive data from two investigator-initiated studies with ZEGERID® (omeprazole/sodium bicarbonate) will be presented in poster sessions at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting taking place in San Diego. These studies were supported by grants from Santarus. [More]

5d2b0a7c-f5c8-4287-8c7e-6b3c509a098b|0|.0

Posted in: Drug Trial News

Tags: Abdominal Pain, Diabetes, Diarrhea, Diet, Exercise, Gastritis, Gastroenterology, Headache, Hypersensitivity, Metformin, Sodium Bicarbonate, Type 2 Diabetes, Ulcerative Colitis

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

23. October 2009 01:15

New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide. [More]

234bfc5b-425f-4fb4-9f5c-5795f4dac7f1|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Cholesterol, Diabetes, Diabetes Mellitus, Exenatide, Growth Hormone, Hospital, Insulin, Insulin Glargine, Lipids, Lipoprotein, Metformin, Nausea, Type 2 Diabetes

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

22. October 2009 08:08

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009. [More]

fc89edfd-87d8-443c-bf50-560729ad8450|0|.0

Posted in: Business / Finance

Tags: Abilify, Angioplasty, Antibody, Apixaban, Arthritis, Cancer, Capecitabine, Cardiology, Chemotherapy, Colorectal Cancer, Diabetes, Diabetes Mellitus, Hemostasis, Hepatitis B, Immunology, Medicaid, Medicare, Metformin, Nutrition, Oncology, Onglyza, Oxaliplatin, Plavix, Prescription Drug, Rheumatoid Arthritis, Saxagliptin, Sprycel, Stroke, Thrombosis, Type 2 Diabetes

Merck's sales increases by 2% in third quarter 2009

22. October 2009 08:06

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61. [More]

cbc59315-7610-4c1c-8b01-4e77137fb8ca|0|.0

Posted in: Business / Finance

Tags: Antiretroviral, Asthma, Cancer, Cervical Cancer, Diabetes, Gardasil, Gastroenteritis, Herpes, Herpes Zoster, Investment, Losartan, Measles, Metformin, Mumps, Nexium, Potassium, Rhinitis, Rotavirus, Shingles, Type 2 Diabetes, Vaccine, Virus, Vytorin, Zocor, Zolinza

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

22. October 2009 00:57

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control. [More]

47e200d9-02a4-4a74-b291-c809d87dfd17|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Antisense, Cancer, Cholesterol, Diabetes, Endocrinology, Hypoglycemia, Insulin, Insulin Resistance, Metabolism, Metformin, microRNA, Sulfonylurea, Type 2 Diabetes, Weight Loss

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

15. October 2009 02:58

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone. [More]

fc68e94e-d90a-4228-82e2-97e607cc13a3|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Actos, Anemia, Bone, Breastfeeding, Cardiovascular Disease, Diabetes, Diabetic Ketoacidosis, Diarrhea, Diet, Exercise, Gastroenterology, Headache, Heart Failure, Hospital, Hypersensitivity, Insomnia, Insulin, Insulin Resistance, Kidney Disease, Metformin, Nausea, Neurology, Pioglitazone, Rheumatology, Sore Throat, Sulfonylurea, Type 2 Diabetes, Urinary Tract Infection, Vomiting

American Recovery and Reinvestment Act funds to support research in numerous health areas

14. October 2009 02:27

As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas. [More]

85842315-e76b-4cd0-b07f-5b0094ecc85e|0|.0

Posted in: Device / Technology News | Healthcare News

Tags: Atrial Fibrillation, Autism, Autoimmune Disease, Breast Cancer, Cancer, Cardiovascular Disease, Colon Cancer, Diabetes, DNA, Education, Electronic Health Record, Gestational Diabetes, Health and Human Services, Heart Failure, Hormonal Therapy, Kidney Disease, Metformin, Obesity, Pregnancy, Prostate Cancer, Stress, Stroke, Weight Loss

Free!

Recent Comments

Twitter

Information

Metformin News and Research

New market research report on Australia's pharmaceuticals and healthcare industry

Erbitux recognized as one of the major clinical cancer advances of 2009

Health Canada approves ONGLYZA for the treatment of type 2 diabetes

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA approves an expanded indication for BYETTA injection

Roche discloses the results of first Phase III clinical study using Taspoglutide

Proper diet and exercise reduce risk of type 2 diabetes

Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Merck's sales increases by 2% in third quarter 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

American Recovery and Reinvestment Act funds to support research in numerous health areas

Recent Articles

Free!

Recent Comments

Twitter

Information

Metformin News and Research

Medical News Cloud

Recent Articles